Frenette, Catherine

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 469

Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium

Mehta, N., Frenette, C., Tabrizian, P., Hoteit, M., Guy, J., Parikh, N., Ghaziani, T. T., Dhanasekaran, R., Dodge, J. L., Natarajan, B., et al. (2021) · Gastroenterology

Hepatocellular Carcinoma Treatment and PrognosisOrgan Transplantation Techniques and Outcomes

Cited by 154

Morphometry confirms fibrosis regression from sustained virologic response to direct-acting antivirals for hepatitis C

Pan, J. J., Bao, F., Du, E., Skillin, C., Frenette, C. T., Waalen, J., Alaparthi, L., Goodman, Z. D., & Pockros, P. J. (2018) · Hepatology Communications

Hepatitis C virus researchLiver Disease Diagnosis and Treatment

Cited by 70